Skip to main content

Table 1 Study schedule

From: A novel endothelial damage inhibitor for the treatment of vascular conduits in coronary artery bypass grafting: protocol and rationale for the European, multicentre, prospective, observational DuraGraft registry

  Screening/ Enrolment CABG/ hospital discharge 1 month Annual follow-up (1–5 years)
Inclusion and exclusion criteria X    
Informed consent X    
Patient characteristics/medical history X    
EuroSCORE II X    
Procedural data   X   
EQ-5D-5 L X    X
Health economic data derived    X X
  1. MACCE Major adverse cardiac and cerebrovascular events (death, non-fatal myocardial infarction, repeat revascularisation, or stroke)